CAR-T

Chapter Outlines

Chapter 2 provides an executive summary of the insights captured during our research. It offers a high-level view on the likely evolution of the CAR-T cell therapy market in the short to mid-term and long term.

Chapter 3 provides a general overview of CAR-T cell therapies. In this section, we have briefly discussed the conventional forms of therapy that are being used for the treatment of various oncological indications. Further, it includes a discussion on the advent and historical evolution of cancer immunotherapy, general manufacturing procedure of CAR-T cell therapies, factors supporting the growing popularity of CAR-T cell based therapies and the challenges associated with such therapies. 

Chapter 4 provides insights on the popularity of CAR-T cell therapies on the social media platform, Twitter. The section highlights the yearly distribution of tweets posted on the platform in the time period 2012-2019, and the most significant events responsible for increase in the volume of tweets each year. Additionally, the chapter highlights the most frequently talked about product candidates, popular disease indications, target antigens, and prolific authors and social media influencers.

Chapter 5 features an assessment of  the CAR-T cell therapies that are currently approved or in different stages of development. It features a detailed analysis of pipeline molecules with respect to the type of developer (industry / non-industry), phase of development (preclinical, phase I, phase I/II, phase II, phase III and approved), therapeutic area (hematological cancer, solid tumor and others), target therapeutic indication (acute lymphoblastic leukemia, non-Hodgkin lymphoma, multiple myeloma, acute myeloid leukemia, brain cancer, chronic lymphocytic leukemia, pancreatic cancer, liver cancer, lung cancer, stomach cancer, ovarian cancer, breast cancer, mesothelioma, colon cancer, Hodgkin lymphoma, sarcoma, bone cancer, melanoma, and others), key target antigen (CD19, BCMA, CD22, CD20, GD2, Meso, CD38, CD123, MUC1, CD30, HER2, GPC3, CD33, EGFR, EGFRvIII, PD-L1, PSMA and others), source of T-cells (autologous / allogeneic), route of administration (intravenous, intratumor, intraperitoneal, intrapleural, intraventricular and others), dose frequency (single dose, multiple dose and split dose), target patient segment (children, adults and seniors), and type of therapy (monotherapy and combination therapy). Further, the chapter provides a list of the most active players (in terms of number of pipeline candidates) and an insightful logo landscape, highlighting product developers in North America, Europe and the Asia Pacific. 

Chapter 6 presents a collection of key insights derived from the study. It includes an insightful  representation highlighting the most popular targets of CAR-T therapies in hematological cancer and solid tumor space. To offer due credit to the work of eminent researchers in this domain, we have mapped the presence of key opinion leaders (who are involved in this field of research) across the globe. In addition, we have presented an analysis of the CAR constructs being used in the clinical CAR-T therapies on the basis of generation of CAR-T therapies (first generation, second generation, third generation and fourth generation), type of binding domain (murine, humanized, fully human and rabbit derived), type of vector (lentivirus, retrovirus, mRNA and other vectors) and type of co-stimulatory domain used.

Chapter 7 presents an analysis of the clinical trials of CAR-T registered across the world, between 2009 and 2019, highlighting the year wise trend and the distribution across different geographies. In addition, we have provided a detailed list of factors that have influenced the growth of CAR-T therapies market in China.

Chapter 8 provides detailed profiles of marketed and mid to late stage CAR-T therapies (phase I/II or above). Each profile features an overview of the therapy, its mechanism of action, dosage information, details on the cost and sales information (wherever available), clinical development plan, and key clinical trial results.

Chapter 9 includes an overview of  the most commonly targeted therapeutic indications, including hematological cancers and solid tumors and features brief discussions on the CAR-T cell therapies being developed against them. The section also highlights key epidemiological facts and the currently available treatment options for each indication.

Chapter 10 provides a list of technology platforms that are either available in the market or under designed for the development of CAR-T cell therapies and a detailed discussion on innovative technology platforms that are being used for the development of T-cell therapies, along with profiles of key technology providers, and a relative competitiveness analysis of different gene editing platforms (used for the development of CAR-T cell therapies), based on various parameters, such as ease of system design, cost of technology, level of toxicity and efficiency of technology.

Chapter 11 features a analysis of the various collaborations and partnerships that have been inked amongst players in this market, in the past few years. Further, the partnership activity in this domain has been analyzed on the basis of the type of partnership model (R&D collaborations, license agreements (specific to technology platforms and product candidates), product development and commercialization agreements, manufacturing agreements, clinical trial collaborations, product supply management agreements and others), companies involved, type of therapy, prominent product candidates involved and regional distribution of the collaborations.

Chapter 12 provides details on the investments and grants that have been awarded to players focused on the development of CAR-T cell therapies. It includes a detailed analysis of the funding instances that have taken place in the period between 2000 to 2020, highlighting the growing interest of venture capital (VC) community and other strategic investors in this domain.

Chapter 13 provides insights on cell therapy manufacturing, highlighting the current challenges in this domain, and the pre-requisites for owning and maintaining cell therapy manufacturing sites. It includes a list of cell therapy manufacturers, covering both contract manufacturing organizations and companies with in-house manufacturing capabilities. For the players mentioned in the chapter, we have included details on location of various manufacturing facilities, the products being manufactured, scale of operation and compliance to cGMP standards.

Chapter 14 highlights our views on the various factors that must be taken into consideration while deciding the prices of CAR-T cell-based therapies. It features discussions on different models / approaches that a pharmaceutical company may choose to follow to decide the price at which their CAR-T cell-based therapy product can be marketed. Additionally, we have provided a brief overview of the reimbursement consideration for CAR-T cell therapies and a case study on the National Institute for Health and Care Excellence (NICE) appraisal of CAR-T therapy.

Chapter 15 features an elaborate discussion on the future commercial opportunity offered by CAR-T cell therapies. It provides an informed market forecast analysis for molecules that are approved or are in phase I/II, phase II and phase III of development, taking into consideration the target patient population, existing / future competition, likely adoption rates and the likely price of different therapies. The chapter also presents a detailed market segmentation on the basis of [A] target indications (non-Hodgkin’s lymphoma, multiple myeloma, chronic lymphocytic leukemia, acute lymphoblastic leukemia, follicular lymphoma, mantle cell lymphoma, hepatocellular carcinoma and colorectal cancer), [B] target antigens (CD19, BCMA, CD19 / CD22, GPC3 and EGFR) and [C] key geographies (North America (US and Canada), Europe (UK, Germany, France, Italy, Spain and rest of EU), Asia Pacific (China, Japan, Australia), Latin America, Latin America, Middle East and North Africa and rest of the world).

Chapter 16 highlights the key promotional strategies that are being implemented by the developers of the marketed products, KYMRIAH® and YESCARTA®. The promotional aspects covered in the chapter include details that are provided on the product website (covering key messages for patients and healthcare professionals), patient support offerings and informative downloadable content.

Chapter 17 includes brief company profiles of the leading players in the CAR-T cell therapy market. Each company profile includes an overview of the developer and brief description of the product portfolio specific to technology portfolio (if available), recent developments related to CAR-T cell therapy and manufacturing capabilities of the companies. Additionally, we have provided details of the strategic / venture capital investments made in these companies.

Chapter 18 is a summary of the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

Chapter 19 is a collection of transcripts of interviews conducted with key stakeholders in the market. In this chapter, we have presented the details of our conversations with Tim Oldham (Chief Executive Officer, Cell Therapies), Vincent Brichard (Vice President, Immuno-Oncology, Celyad), Xian-Bao Zhan (Professor of Medicine and Director, Department of Oncology, Changhai Hospital), Troels Jordansen (Chief Executive Officer, Glycostem Therapeutics), Wei (William) Cao (Chief Executive Officer, Gracell Biotechnologies), Adrian Bot (Vice President, Scientific Affairs, Kite Pharma), Aino Kalervo (Competitive Intelligence Manager, Strategy & Business Development, Theravectys), Miguel Forte (Chief Operating Officer, TxCell), Enkhtsetseg Purev (Assistant Professor of Medicine, University of Colorado) and Brian Dattilo (Manager of Business Development, Waisman Biomanufacturing).

Chapter 20 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 21 is an appendix, which contains the list of companies and organizations mentioned in the report.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Pillars of Cancer Therapy
3.3. Overview of Immunotherapy
3.4. Fundamentals of Cancer Immunotherapy
3.5. Classification of Cancer Immunotherapies
3.5.1. By Mechanism of Action
3.5.1.1. Active Immunotherapy
3.5.1.2. Passive Immunotherapy

3.5.2. By Type of Target
3.5.3. By Approach
3.5.3.1. Activation and Suppression Immunotherapy

3.5.4. By Product Class
3.5.4.1. Monoclonal Antibodies
3.5.4.2. Bispecific Antibodies
3.5.4.3. Cytokines
3.5.4.4. Oncolytic Virus Therapy
3.5.4.5. Therapeutic Cancer Vaccines
3.5.4.6. Cell-based Therapies

3.6. T-Cell Immunotherapies
3.6.1. Historical Evolution
3.6.2. Key Considerations for Developing T-Cell Immunotherapies
3.6.3. Strategies Employed for the Redirection of T-Cells
3.6.4. Manufacturing of Engineered T-Cells
3.6.5. T-Cell Transduction and Transfection Methods
3.6.5.1. Retroviral Vectors
3.6.5.2. Lentiviral Vectors
3.6.5.3. Non-viral Transfection Methods

3.7. Chimeric Antigen Receptor T-Cell Therapy (CAR-T)
3.7.1. History of Development
3.7.2. Anatomical Layout of CAR
3.7.2.1. Ectodomain
3.7.2.2. Transmembrane (TM) Domain
3.7.2.3. Endodomain

3.7.3. Development of CAR-T Cells
3.7.4. Universal CAR-T Cells
3.7.5. Route of Administration of CAR-T Cell Therapies
3.7.6. Case Study: CD19 CAR-T Cell Therapies
3.7.6.1. Other Important Biological Targets for CAR Development

3.7.7. Challenges Associated with CAR-T Cell Therapies
3.7.7.1. Competitive Risks
3.7.7.2. Clinical Risks
3.7.7.3. Regulatory Risks
3.7.7.4. Commercial Risks

4. EMERGING TRENDS ON SOCIAL MEDIA
4.1. Chapter Overview
4.2. CAR-T Cell Therapies: Trends on Twitter
4.2.1. Historical Trend in Volume of Tweets
4.2.2. Trending Words / Phrases on Twitter
4.2.3. Most Popular Drugs on Twitter
4.2.4. Most Prolific Authors on Twitter
4.2.5. Most Popular Indications and Target Antigens

5. MARKET LANDSCAPE
5.1. Chapter Overview
5.2. CAR-T Cell Therapies: Overall Market Landscape
5.2.1. Analysis by Type of Developer
5.2.2. Analysis by Phase of Development
5.2.3. Analysis by Therapeutic Area
5.2.4. Analysis by Popular Target Indications
5.2.5. Analysis by Popular Target Antigens
5.2.6. Analysis by Source of T-Cells
5.2.7. Analysis by Route of Administration
5.2.8. Analysis by Dose Frequency
5.2.9. Analysis by Target Patient Segment
5.2.10. Analysis by Type of Therapy
5.2.11. Key Industry Players: Distribution by Number of Therapies in Pipeline
5.2.12. Key Non-Industry Players: Distribution by Number of Therapies in Pipeline

6. KEY INSIGHTS
6.1. Chapter Overview
6.2. CAR-T Cell Therapies: Competitive Analysis by Popular Target Antigens
6.2.1. Popular Targets Related to Hematological Malignancies
6.2.1.1. Competitive Landscape of CD19 CAR-T Cell Therapies
6.2.1.2. Clinical Trial Results of Prominent CD19 CAR-T Cell Therapies
6.2.1.3. Competitive Landscape of BCMA CAR-T Cell Therapies
6.2.1.4. Clinical Trial Results of Prominent BCMA CAR-T Cell Therapies

6.2.2. Popular Targets Related to Solid Tumors 
6.2.2.1. Competitive Landscape of Meso CAR-T Cell Therapies
6.2.2.2. Clinical Trial Results of Prominent Meso CAR-T Cell Therapies
6.2.2.3. Competitive Landscape of GD2 CAR-T Cell Therapies
6.2.2.4. Clinical Trial Results of Prominent GD2 CAR-T Cell Therapies

6.3. CAR-T Cell Therapies: Key Opinion Leaders
6.3.1. CAR-T Cell Therapies: Most Prominent Key Opinion Leaders

6.4. CAR-T Cell Therapies: CAR Construct Analysis
6.4.1. Analysis by Generation of CAR
6.4.2. Analysis by Type of scFv Antibody
6.4.3. Analysis by Type of Vector
6.4.4. Analysis by Type of Co-Stimulatory Domain(s)

7. CLINICAL TRIAL ANALYSIS
7.1. Chapter Overview
7.2. CAR-T Cell Therapies: Clinical Trial Analysis
7.2.1. Methodology
7.2.2. Analysis by Trial Registration Year
7.2.3. Geographical Analysis by Number of Registered Trials
7.2.4. Case Study: CAR-T Cell Therapy Market in China
7.2.4.1. Factors Contributing to the Growth of CAR-T Cell Therapy Trials in China

8. CAR-T CELL THERAPY PROFILES
8.1. Chapter Overview
8.2. KYMRIAH® / Tisagenlecleucel / CTL019 (Novartis)
8.2.1. Therapy Overview
8.2.1.1. History of Development
8.2.2. Current Status of Development 
8.2.3. Key Clinical Trial Results
8.2.4. Dosage Regimen, Price and Manufacturing

8.3. YESCARTA® / Axicabtagene Ciloleucel / KTE-C19 (Kite Pharma)
8.3.1. Therapy Overview
8.3.1.1. History of Development
8.3.2. Current Status of Development 
8.3.3. Key Clinical Trial Results
8.3.4. Dosage Regimen, Price and Manufacturing

8.4. TECARTUS® / Brexucabtagene Autoleucel (Kite Pharma)
8.4.1. Therapy Overview
8.4.2. Current Status of Development 
8.4.3. Key Clinical Trial Results
8.4.4. Dosage Regimen, Price and Manufacturing

8.5. JCAR (Juno Therapeutics (a Bristol Myers Squibb Company))
8.5.1. Therapy Overview
8.5.1.1. CAR-T Design
8.5.2. Current Status of Development 
8.5.3. Key Clinical Results
8.5.3.1. JCAR014
8.5.3.2. JCAR017
8.5.3.3. JCAR018
8.5.3.4. JCARH125
8.5.4. Dosage Regimen and Manufacturing

8.6. Idecabtagene Vicleucel / bb2121 (bluebird bio / Bristol-Myers Squibb)
8.6.1. Therapy Overview
8.6.2. Current Status of Development 
8.6.3. Key Clinical Trial Results
8.6.4. Dosage Regimen and Manufacturing

8.7. Ciltacabtagene Autoleucel / LCAR-B38M CAR-T / JNJ-68284528 (Nanjing Legend Biotech / Janssen Biotech)
8.7.1. Therapy Overview
8.7.2. Current Status of Development 
8.7.3. Key Clinical Trial Results
8.7.4. Dosage Regimen and Manufacturing

8.8. TBI-1501 / CD19 CAR-T Cell Therapy (Takara Bio)
8.8.1. Therapy Overview
8.8.2. Current Status of Development 
8.8.3. Key Clinical Trial Results
8.8.4. Dosage Regimen and Manufacturing

8.9. Next Generation CAR-T Cell therapies (Autolus)
8.9.1. Therapy Overview
8.9.2. Current Status of Development 
8.9.3. Key Clinical Trial Results
8.9.3.1. AUTO1
8.9.3.2. AUTO3
8.9.4. Dosage Regimen and Manufacturing

8.10. CAR-T Cell Therapies (Sinobioway Cell Therapy)
8.10.1. Therapy Overview
8.10.2. Current Status of Development 
8.10.3. Dosage Regimen and Manufacturing

9. KEY THERAPEUTIC AREAS FOR CAR-T CELL THERAPIES
9.1. Chapter Overview
9.2. Hematological Malignancies
9.2.1. Leukemia and Lymphoma
9.2.1.1. Leukemia: Introduction and Epidemiology
9.2.1.1.1. Acute Myeloid Leukemia (AML)
9.2.1.1.2. Chronic Myeloid Leukemia (CML)
9.2.1.1.3. Acute Lymphocytic Leukemia (ALL)
9.2.1.1.4. Chronic Lymphocytic Leukemia (CLL)

9.2.1.2. Lymphoma: Introduction and Epidemiology
9.2.1.3. Current Treatment Landscape
9.2.1.3.1. Targeted Therapies

9.2.1.4. CAR-T Cell Therapies and Affiliated Research Landscape
9.2.1.4.1. CAR-T Cell Therapies and Leukemia / Lymphoma

9.2.2. Multiple Myeloma
9.2.2.1. Introduction and Epidemiology
9.2.2.2. Current Treatment Landscape
9.2.2.3. CAR-T Cell Therapies and Affiliated Research Landscape

9.3. Solid Tumors
9.3.1. Metastatic Melanoma
9.3.1.1. Introduction and Epidemiology
9.3.1.2. Current Treatment Landscape
9.3.1.3. CAR-T Cell Therapies and Affiliated Research Landscape

9.3.2. Lung Cancer
9.3.2.1. Introduction and Epidemiology
9.3.2.2. Current Treatment Landscape
9.3.2.3. CAR-T Cell Therapies and Affiliated Research Landscape

9.3.3. Pancreatic Cancer
9.3.3.1. Introduction and Epidemiology
9.3.3.2. Current Treatment Landscape
9.3.3.3. CAR-T Cell Therapies and Affiliated Research Landscape

9.3.4. Liver Cancer
9.3.4.1. Introduction and Epidemiology
9.3.4.1. Current Treatment Landscape
9.3.4.2. CAR-T Cell Therapies and Affiliated Research Landscape

9.3.5. Breast Cancer
9.3.5.1. Introduction and Epidemiology
9.3.5.2. Current Treatment Landscape
9.3.5.3. CAR-T Cell Therapies and Affiliated Research Landscape

9.3.6. Ovarian Cancer
9.3.6.1. Introduction and Epidemiology
9.3.6.2. Current Treatment Landscape
9.3.6.3. CAR-T Cell Therapies and Affiliated Research Landscape

9.3.7. Bladder Cancer
9.3.7.1. Introduction and Epidemiology
9.3.7.2. Current Treatment Landscape
9.3.7.3. CAR-T Cell Therapies and Affiliated Research Landscape

9.3.8. Kidney Cancer
9.3.8.1. Introduction and Epidemiology
9.3.8.2. Current Treatment Landscape
9.3.8.3. CAR-T Cell Therapies and Affiliated Research Landscape

10. EMERGING TECHNOLOGIES
10.1. Chapter Overview
10.2. Genome Editing Technologies
10.2.1. Applications of Genome Editing Technologies 
10.2.2. Emerging Technology Platforms for CAR-T Cell Therapy Development and Production
10.2.2.1. CRISPR / Cas9 System
10.2.2.1.1. Key Components and Function
10.2.2.1.2. Mechanism of Action
10.2.2.1.3. Targeting Efficiency and Challenges
10.2.2.1.4. Next-GEN CRISPR Technology
10.2.2.1.5. Technology Providers
10.2.2.1.5.1. Editas Medicine
10.2.2.1.5.2. Intellia Therapeutics
10.2.2.1.5.3. CRISPR Therapeutics
10.2.2.1.5.4. Beam Therapeutics
10.2.2.1.5.5. Gracell Biotechnologies

10.2.2.2. TALENs
10.2.2.2.1. Key Components and Function
10.2.2.2.2. Mechanism of Action
10.2.2.2.3. Advantages and Challenges
10.2.2.2.4. Technology Providers
10.2.2.2.4.1. Cellectis
10.2.2.2.4.2. Editas Medicine

10.2.2.3. megaTAL
10.2.2.3.1. Technology Providers
10.2.2.3.1.1. bluebird bio

10.2.2.4. Zinc Finger Nuclease
10.2.2.4.1. Technology Providers
10.2.2.4.1.1. Sangamo Therapeutics

10.2.3. Competitive Analysis: Gene Editing Platforms

10.3. Designing CAR-T Cell Therapies with Improved Characteristics
10.3.1. Technologies for Targeting Multiple Cancers
10.3.1.1. Antibody Coupled T-Cell Receptor
10.3.1.1.1. Unum Therapeutics

10.3.1.2. NKR-T Platform
10.3.1.2.1. Celyad Oncology
10.3.1.2.2. Glycostem

10.3.2. Technologies for Improved Safety
10.3.2.1. Armored CAR and EGFRt Technology
10.3.2.1.1. Juno Therapeutics

10.3.2.2. RheoSwitch Therapeutic System
10.3.2.2.1. Intrexon

10.3.2.3. Inducible Caspase 9 Safety Switch
10.3.2.3.1. Bellicum Pharmaceuticals
10.3.2.3.1.1. CaspaCIDe Technology
10.3.2.3.1.2. CIDeCAR Technology
10.3.2.3.1.3. GoCAR-T Technology

10.3.2.3. On-Off Switch, Multiple Companies
10.3.2.3.1. Inhibitory CAR (iCAR) (Juno Therapeutics)
10.3.2.3.2. On-Off Switch (Theravectys)

10.3.2.4. Other Technologies to Improve CAR-T Safety

10.3.3. Allogeneic Technologies
10.3.3.1. CIK CAR-T Cells (Formula Pharmaceuticals)
10.3.3.2. Allogeneic Platform (Celyad)
10.3.3.3. Allogeneic Platform (Cellectis)

11. PARTNERSHIPS AND COLLABORATIONS
11.1. Chapter Overview
11.2. Partnership Models
11.3. CAR-T Cell Therapy Market: List of Partnerships and Collaborations
11.3.1. Analysis by Year of Partnership
11.3.2. Analysis by Type of Partnership
11.3.3. Most Popular Products
11.3.4. Most Active Industry Players: Analysis by Number of Partnerships
11.3.5. Most Active Non-Industry Players: Analysis by Number of Partnerships
11.3.6. Most Active Contract Manufacturers: Analysis by Number of Manufacturing 
11.3.7. Regional Analysis
11.3.8. Intercontinental and Intracontinental Agreements

12. FUNDING AND INVESTMENT ANALYSIS
12.1. Chapter Overview
12.2. Types of Funding
12.3. CAR-T Cell Therapy Market: Funding and Investment Analysis
12.3.1. Analysis by Year of Investment
12.3.2. Analysis by Amount Invested
12.3.3. Analysis by Type of Funding
12.3.4. Most Active Players: Analysis by Number of Funding Instances
12.3.5. Analysis by Type of Investor
12.3.6. Most Active Investors: Analysis by Number of Funding Instances
12.3.7. Regional Analysis by Amount Invested

13. CASE STUDY: CELL THERAPY MANUFACTURING
13.1. Chapter Overview
13.2. Overview of Cell Therapy Manufacturing
13.3. Cell Therapy Manufacturing Models
13.3.1. Centralized Manufacturing Model
13.3.2. Decentralized Manufacturing Model

13.4. Scalability of Cell Therapy Manufacturing Processes
13.4.1. Scale-Up
13.4.2. Scale-Out

13.5. Types of Cell Therapy Manufacturers
13.6. Key Challenges Associated with Manufacturing of Cell Therapies
13.7. Important Factors for Cell Therapy Manufacturing
13.7.1. Characterization
13.7.2. Cost of Goods

13.8. Automation of Cell Therapy Manufacturing Process
13.9. Cell Therapy Manufacturing Supply Chain
13.10. Companies with In-House Capabilities
13.11. Contract Manufacturers
13.12. Regulatory Landscape

14. COST PRICE ANALYSIS
14.1. Chapter Overview
14.2. Factors Contributing to the High Price of Cell / Gene Therapies
14.3. Pricing Models for CAR-T Cell Therapies
14.3.1. Based on Associated Costs
14.3.2. Based on Availability of Competing Products
14.3.3. Based on Target Patient Segment
14.3.4. Based on the Opinions of Industry Experts

14.4. Reimbursement-related Considerations for CAR-T Cell Therapies
14.4.1. Case Study: The National Institute for Health and Care Excellence (NICE) Appraisal of CAR-T Therapies

15. MARKET SIZING AND OPPORTUNITY ANALYSIS
15.1. Chapter Overview
15.2. Scope and Limitations
15.3. Key Assumptions and Forecast Methodology
15.4. Overall CAR-T Cell Therapy Market, 2021-2030
15.4.1. CAR-T Cell Therapies Market: Distribution by Target Indication
15.4.2. CAR-T Cell Therapies Market: Distribution by Target Antigen
15.4.3. CAR-T Cell Therapies Market: Distribution by Key Players
15.4.4. CAR-T Cell Therapies Market: Distribution by Geography
15.4.5. Product Wise Sales Forecast

15.4.5.1. KYMRIAH® (Novartis)
15.4.5.1.1. Target Patient Population
15.4.5.1.2. Sales Forecast (USD Million)
15.4.5.1.3. Net Present Value (USD Million)
15.4.5.1.4. Value Creation Analysis

15.4.5.2. YESCARTA® (Gilead Sciences)
15.4.5.2.1. Target Patient Population
15.4.5.2.2. Sales Forecast (USD Million)
15.4.5.2.3. Net Present Value (USD Million)
15.4.5.2.4. Value Creation Analysis

15.4.5.3. Tecartus / Brexucabtagene Autoleucel (Gilead Sciences)
15.4.5.3.1. Target Patient Population
15.4.5.3.2. Sales Forecast (USD Million)
15.4.5.3.3. Net Present Value (USD Million)
15.4.5.3.4. Value Creation Analysis

15.4.5.4. BREYANZI® / Lisocabtagene Maraleucel / JCAR017JCAR017 (Bristol Myers Squibb / Juno Therapeutics)
15.4.5.4.1. Target Patient Population
15.4.5.4.2. Sales Forecast (USD Million)
15.4.5.4.3. Net Present Value (USD Million)
15.4.5.4.4. Value Creation Analysis

15.4.5.5. Idecabtagene Vicleucel / bb2121 (bluebird bio / Bristol Myers Squibb)
15.4.5.5.1. Target Patient Population
15.4.5.5.2. Sales Forecast (USD Million)
15.4.5.5.3. Net Present Value (USD Million)
15.4.5.5.4. Value Creation Analysis

15.4.5.6. Ciltacabtagene Autoleucel / LCAR-B38M CAR-T (Nanjing Legend Biotech / Janssen)
15.4.5.6.1. Target Patient Population
15.4.5.6.2. Sales Forecast (USD Million)
15.4.5.6.3. Net Present Value (USD Million)
15.4.5.6.4. Value Creation Analysis

15.4.5.7. MB-CART19.1 (Miltenyi Biotec)
15.4.5.7.1. Target Patient Population
15.4.5.7.2. Sales Forecast (USD Million)
15.4.5.7.3. Net Present Value (USD Million)
15.4.5.7.4. Value Creation Analysis

15.4.5.8. Descartes-11 (Cartesian Therapeutics)
15.4.5.8.1. Target Patient Population
15.4.5.8.2. Sales Forecast (USD Million)
15.4.5.8.3. Net Present Value (USD Million)
15.4.5.8.4. Value Creation Analysis

15.4.5.9. CD19 CAR-T (Sinobioway Cell Therapy)
15.4.5.9.1. Target Patient Population
15.4.5.9.2. Sales Forecast (USD Million)
15.4.5.9.3. Net Present Value (USD Million)
15.4.5.9.4. Value Creation Analysis

15.4.5.10. AUTO1 (Autolus)
15.4.5.10.1. Target Patient Population
15.4.5.10.2. Sales Forecast (USD Million)
15.4.5.10.3. Net Present Value (USD Million)
15.4.5.10.4. Value Creation Analysis

15.4.5.11. AUTO3 (Autolus)
15.4.5.11.1. Target Patient Population
15.4.5.11.2. Sales Forecast (USD Million)
15.4.5.11.3. Net Present Value (USD Million)
15.4.5.11.4. Value Creation Analysis

15.4.5.12. GPC3 CAR-T (Shanghai GeneChem)
15.4.5.12.1. Target Patient Population
15.4.5.12.2. Sales Forecast (USD Million)
15.4.5.12.3. Net Present Value (USD Million)
15.4.5.12.4. Value Creation Analysis

15.4.5.13. BCMA CAR-T (The Pregene (ShenZhen) Biotechnology)
15.4.5.13.1. Target Patient Population
15.4.5.13.2. Sales Forecast (USD Million)
15.4.5.13.3. Net Present Value (USD Million)
15.4.5.13.4. Value Creation Analysis

15.4.5.14. CD19 CAR-T (The Pregene (ShenZhen) Biotechnology)
15.4.5.14.1. Target Patient Population
15.4.5.14.2. Sales Forecast (USD Million)
15.4.5.14.3. Net Present Value (USD Million)
15.4.5.14.4. Value Creation Analysis

15.4.5.15. CD19 CAR-T (Shanghai Bioray Laboratory)
15.4.5.15.1. Target Patient Population
15.4.5.15.2. Sales Forecast (USD Million)
15.4.5.15.3. Net Present Value (USD Million)
15.4.5.15.4. Value Creation Analysis

15.4.5.16. Humanized CD19 CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology)
15.4.5.16.1. Target Patient Population
15.4.5.16.2. Sales Forecast (USD Million)
15.4.5.16.3. Net Present Value (USD Million)
15.4.5.16.4. Value Creation Analysis

15.4.5.17. PCAR-019 (PersonGen BioTherapeutics)
15.4.5.17.1. Target Patient Population
15.4.5.17.2. Sales Forecast (USD Million)
15.4.5.17.3. Net Present Value (USD Million)
15.4.5.17.4. Value Creation Analysis

15.4.5.18. TBI-1501 (Takara Bio)
15.4.5.18.1. Target Patient Population
15.4.5.18.2. Sales Forecast (USD Million)
15.4.5.18.3. Net Present Value (USD Million)
15.4.5.18.4. Value Creation Analysis

15.4.5.19. IM19 CAR-T (Beijing Immunochina Medical Science & Technology)
15.4.5.19.1. Target Population
15.4.5.19.2. Sales Forecast (USD Million)
15.4.5.19.3. Net Present Value (USD Million)
15.4.5.19.4. Value Creation Analysis

15.4.5.20. CCT301 CAR-T Cell Therapy (Shanghai Sinobioway Sunterra Biotech)
15.4.5.20.1. Target Patient Population
15.4.5.20.2. Sales Forecast (USD Million)
15.4.5.20.3. Net Present Value (USD Million)
15.4.5.20.4. Value Creation Analysis

15.4.5.21. BinD19 (Shenzhen BinDeBio)
15.4.5.21.1. Target Patient Population
15.4.5.21.2. Sales Forecast (USD Million)
15.4.5.21.3. Net Present Value (USD Million)
15.4.5.21.4. Value Creation Analysis

15.4.5.22. CARCIK-CD19 (Formula Pharmaceuticals)
15.4.5.22.1. Target Patient Population
15.4.5.22.2. Sales Forecast (USD Million)
15.4.5.22.3. Net Present Value (USD Million)
15.4.5.22.4. Value Creation Analysis

15.4.5.23. EGFR CAR-T Cell Therapy (The Beijing Pregene Science and Technology)
15.4.5.23.1. Target Patient Population
15.4.5.23.2. Sales Forecast (USD Million)
15.4.5.23.3. Net Present Value (USD Million)
15.4.5.23.4. Value Creation Analysis

15.4.5.24. Anti-MUC1 CAR-T Cell Therapy (Guangzhou Anjie Biomedical Technology)
15.4.5.24.1. Target Patient Population
15.4.5.24.2. Sales Forecast (USD Million)
15.4.5.24.3. Net Present Value (USD Million)
15.4.5.24.4. Value Creation Analysis

15.4.5.25. PBCAR269A (Precision BioSciences and Servier)
15.4.5.25.1. Target Patient Population
15.4.5.25.2. Sales Forecast (USD Million)
15.4.5.25.3. Net Present Value (USD Million)
15.4.5.25.4. Value Creation Analysis

15.4.5.26. CD123 CAR-T cell Therapy (Chongqing Precision Biotechnology)
15.4.5.26.1. Target Patient Population
15.4.5.26.2. Sales Forecast (USD Million)
15.4.5.26.3. Net Present Value (USD Million)
15.4.5.26.4. Value Creation Analysis

15.4.5.27. BCMA CAR-T (Chongqing Precision Biotech)
15.4.5.27.1. Target Patient Population
15.4.5.27.2. Sales Forecast (USD Million)
15.4.5.27.3. Net Present Value (USD Million)
15.4.5.27.4. Value Creation Analysis

15.4.5.28. P-BCMA-101 (Poseida Therapeutics and California Institute for Regenerative Medicine)
15.4.5.28.1. Target Patient Population
15.4.5.28.2. Sales Forecast (USD Million)
15.4.5.28.3. Net Present Value (USD Million)
15.4.5.28.4. Value Creation Analysis

16. PROMOTIONAL ANALYSIS
16.1. Chapter Overview
16.2. Channels Used for Promotional Campaigns
16.3. Summary of Product Website Analysis
16.4. Summary of Patient Support Services and Informative Downloads

16.5. KYMRIAH®: Promotional Analysis
16.5.1. Drug Overview
16.5.2. Product Website Analysis
16.5.2.1. Messages for Healthcare Professionals
16.5.2.2. Messages for Patients
16.5.3. Patient Support Services and Informative Downloads
16.5.4. Other Promotional Activities
16.5.4.1. Presence in Conferences

16.6. YESCARTA®: Promotional Analysis
16.6.1. Drug Overview
16.6.2. Product Website Analysis
16.6.2.1. Messages for Healthcare Professionals
16.6.2.3. Messages for Patients
16.6.3. Patient Support Services and Informative Downloads
16.6.4. Other Promotional Activities
16.6.4.1. Presence in Conferences

17. COMPANY PROFILES
17.1. Chapter Overview
17.2. Autolus
17.3. bluebird bio
17.4. CARsgen Therapeutics
17.5. Celgene (A Bristol Myers Squibb Company)
17.6. Cellectis
17.7. Cellular Biomedicine Group
17.8. Innovative Cellular Therapeutics
17.9. Kite Pharma (A Gilead Sciences Company)
17.10. Kuur Therapeutics
17.11. Noile-Immune Biotech
17.12. Novartis
17.13. Shanghai Genechem
17.14. Sinobioway Cell Therapy
17.15. Takara Bio
17.16. Ziopharm Oncology

18. CONCLUDING REMARKS
18.1. Chapter Overview

19. EXECUTIVE INSIGHTS
19.1. Chapter Overview
19.2. Cell Therapies
19.2.1. Interview Transcript: Tim Oldham, Chief Executive Officer

19.3. Celyad
19.3.1. Interview Transcript: Vincent Brichard, Vice President, Immuno-Oncologys

19.4. Changhai Hospital
19.4.1. Interview Transcript: Xian-Bao Zhan, Professor of Medicine and Director, Department of Oncology

19.5. Glycostem Therapeutics
19.5.1. Interview Transcript: Troels Jordansen, Chief Executive Officer

19.6. Gracell Biotechnologies
19.6.1. Interview Transcript: Wei (William) Cao, Chief Executive Officer

19.7. Kite Pharma
19.7.1. Interview Transcript: Adrian Bot, Vice President, Scientific Affairs

19.8. Theravectys
19.8.1. Interview Transcript: Aino Kalervo, Competitive Intelligence Manager, Strategy & Business Development

19.9. TxCell
19.9.1. Interview Transcript: Miguel Forte, Chief Operating Officer

19.10. University of Colorado
19.10.1. Interview Transcript: Enkhtsetseg Purev, Assistant Professor of Medicine

19.11. Waisman Biomanufacturing
19.11.1. Interview Transcript: Brian Dattilo, Manager of Business Development

20. APPENDIX 1: TABULATED DATA

21. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 3.1 Pillars of Cancer Therapy
Figure 3.2 Differences between Active and Passive Immunotherapies
Figure 3.3 Differences between Specific and Non-Specific Immunotherapies
Figure 3.4 Strategies Employed for the Redirection of T-Cells
Figure 3.5 T-Cell Manufacturing: General Procedure
Figure 3.6 Historical Development of CAR-T cells
Figure 3.7 Structure of Chimeric Antigen Receptor
Figure 3.8 Chimeric Antigen Receptors: Structural Variations across Different Generations
Figure 3.9 CAR-T Cell Therapies: Development Process
Figure 3.10 Challenges Associated with CAR-T Cell Therapies
Figure 4.1 Social Media Analysis: Historical Trend on Twitter, January 2012-April 2019
Figure 4.2 Social Media Analysis: Trending Words / Phrases on Twitter
Figure 4.3 Social Media Analysis: Most Popular Drug Candidates on Twitter
Figure 4.4 Social Media Analysis: Most Prolific Authors on Twitter
Figure 4.5 Average Number of Likes, Re-tweets and Comments Related to CAR-T Cell Therapies
Figure 4.6 Social Media Analysis: Most Popular Indications and Target Antigen
Figure 5.1 CAR-T Cell Therapies: Distribution by Type of Developer
Figure 5.2 CAR-T Cell Therapies: Distribution by Phase of Development
Figure 5.3 CAR-T Cell Therapies: Distribution by Therapeutic Area
Figure 5.4 CAR-T Cell Therapies: Distribution by Popular Target Indications
Figure 5.5 CAR-T Cell Therapies: Distribution by Popular Target Antigens
Figure 5.6 CAR-T Cell Therapies: Distribution by Source of T-Cells
Figure 5.7 CAR-T Cell Therapies: Distribution by Route of Administration
Figure 5.8 CAR-T Cell Therapies: Distribution by Dose Frequency
Figure 5.9 CAR-T Cell Therapies: Distribution by Target Patient Segment
Figure 5.10 CAR-T Cell Therapies: Distribution by Type of Therapy
Figure 5.11 CAR-T Cell Therapies: Active Industry Players by Number of Therapies in Clinical Development
Figure 5.12 CAR-T Cell Therapies: Active Industry Players by Number of Therapies in Preclinical Development
Figure 5.13 CAR-T Cell Therapies: Active Non-Industry Players by Number of Therapies in Clinical Development
Figure 5.14 CAR-T Cell Therapies: Active Non-Industry Players by Number of Therapies in Preclinical Development
Figure 6.1 CAR-T Cell Therapies: Popular Targets in Hematological Malignancies
Figure 6.2 CAR-T Cell Therapies: Popular Targets in Solid Tumor
Figure 6.3 CAR-T Cell Therapies: Geographical Distribution of Key Opinion Leaders
Figure 6.4 CAR-T Cell Therapies: Prominent Key Opinion Leaders
Figure 6.5 CAR-Construction: Analysis by Generation of CAR-T Therapies
Figure 6.6 CAR-Construction: Analysis by Type of scFv Antibody used in CAR-T Therapies
Figure 6.7 CAR-Construction: Analysis by Type of Vector
Figure 6.8 CAR-Construction: Analysis by Type of Co-Stimulatory Domain(s)
Figure 7.1 CAR-T Cell Therapy Clinical Trials: Distribution by Trial Registration Year
Figure 7.2 CAR-T Cell Therapy Clinical Trials: Distribution by Year of Registration and Geography (Pre-2016 and 2016-2019)
Figure 8.1 Manufacturing of CD19 CAR-T Cells: Process Comparison
Figure 9.1 Leukemia: Classification
Figure 9.2 Leukemia: Global Epidemiological Distribution
Figure 9.3 Lymphoma: Global Epidemiological Distribution
Figure 9.4 Multiple Myeloma: Global Epidemiological Distribution
Figure 9.5 Melanoma: Global Epidemiological Distribution
Figure 9.6 Lung Cancer: Classification
Figure 9.7 Lung Cancer: Global Epidemiological Distribution
Figure 9.8 Pancreatic Cancer: Global Epidemiological Distribution
Figure 9.9 Liver Cancer: Global Epidemiological Distribution
Figure 9.10 Breast Cancer: Global Epidemiological Distribution
Figure 9.11 Ovarian Cancer: Global Epidemiological Distribution
Figure 9.12 Bladder Cancer: Global Epidemiological Distribution
Figure 9.13 Kidney Cancer: Global Epidemiological Distribution
Figure 10.1 Genome Editing Technologies: Applications
Figure 10.2 Genome Editing: Emerging Technology Platforms Used in CAR-T Cell Therapies
Figure 10.3 Competitiveness Analysis: Gene Editing Platforms
Figure 10.4 CAR-T Cell Therapies: Key Technologies to Enhance Features / Characteristics
Figure 10.5 Cellectis: Properties of Enhanced T-Cell Platform
Figure 10.6 Cellectis: Allogenic CAR-T Platform, Comparison with Autologous CAR-T Platform
Figure 11.1 Partnerships and Collaborations: Cumulative Year-Wise Trend, 2005-2020
Figure 11.2 Partnerships and Collaborations: Year-Wise Distribution by Type of Partner, Pre-2013-2020
Figure 11.3 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 11.4 Partnerships and Collaborations: Distribution by Type of Partnership, Pre-2015 and 2015-2020
Figure 11.5 Partnerships and Collaborations: Distribution by Individual Products
Figure 11.6 Partnerships and Collaborations: Most Active Industry Players
Figure 11.7 Partnerships and Collaborations: Most Active Non-Industry Players
Figure 11.8 Partnerships and Collaborations: Most Active Contract Manufacturers
Figure 11.9 Partnerships and Collaborations: Intercontinental and Intracontinental Manufacturing Agreements
Figure 11.10 Partnerships and Collaborations: Regional Distribution
Figure 11.11 Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
Figure 12.1 Funding and Investment Analysis: Cumulative Year-wise Trend of Funding Instances, Pre 2013-2020 (till October)
Figure 12.2 Funding and Investment Analysis: Cumulative Distribution of Amount Invested, Pre 2013-2020 (USD Million)
Figure 12.3 Funding and Investment Analysis: Distribution of Instances by Type of Funding
Figure 12.4 Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding (USD Million)
Figure 12.5 Most Active Players: Distribution by Number of Funding Instances
Figure 12.6 Funding and Investment: Distribution by Types of Investor
Figure 12.7 Most Active Players: Distribution by Number of Instances
Figure 12.8 Funding and Investment Analysis: Distribution by Geography
Figure 12.9 Funding and Investment Analysis: Distribution of Amount Invested across Different Countries (USD Million)
Figure 13.1 Steps in Cell Therapy Manufacturing
Figure 13.2 Centralized Manufacturing: Process Model
Figure 13.3 Decentralized Manufacturing: Process Model
Figure 13.4 Cell Therapy Manufacturing: Types of Manufacturers
Figure 13.5 Cell Therapy Manufacturing: Challenges and Drivers
Figure 13.6 Cell Therapies: Potency as Critical Quality Attribute
Figure 13.7 Cell Therapy Manufacturing: Supply Chain Model
Figure 13.8 Cell Therapy Manufacturing: Supply Chain Risk Assessment Considerations
Figure 14.1 Targeted Therapies: Pricing Model Based on Patient Segment
Figure 15.1 Overall CAR-T Cell Therapies Market, 2021-2030 (USD Billion)
Figure 15.2 CAR-T Cell Therapies Market: Distribution by Target Indication (USD Billion)
Figure 15.3 CAR-T Cell Therapies Market: Distribution by Target Antigen (USD Billion)
Figure 15.4 CAR-T Cell Therapies Market: Key Players (USD Billion)
Figure 15.5 CAR-T Cell Therapies Market: Distribution by Target Geography (USD Billion)
Figure 15.6 KYMRIAH® (Novartis): Current Status of Development
Figure 15.7 KYMRIAH® (Novartis) Sales Forecast, till 2030 (USD Million)
Figure 15.8 YESCARTA® (Gilead Sciences): Current Status of Development
Figure 15.9 YESCARTA® (Gilead Sciences) Sales Forecast, till 2030 (USD Million)
Figure 15.10 TECARTUS® (Gilead Sciences): Current Status of Development
Figure 15.11 TECARTUS®: (Gilead Sciences) Sales Forecast, till 2030 (USD Million)
Figure 15.12 BREYANZI® / Lisocabtagene Maraleucel / JCAR017JCAR017 (Bristol Myers Squibb / Juno Therapeutics): Current Status of Development
Figure 15.13 BREYANZI® / Lisocabtagene Maraleucel / JCAR017JCAR017 (Bristol Myers Squibb / Juno Therapeutics) Sales Forecast, till 2030 (USD Million)
Figure 15.14 Idecabtagene Vicleucel / bb2121 (bluebird bio / Bristol Myers Squibb): Current Statusof Development
Figure 15.15 Idecabtagene Vicleucel / bb2121 (bluebird bio / Bristol Myers Squibb) Sales Forecast, till 2030 (USD Million)
Figure 15.16 Ciltacabtagene Autoleucel / LCAR-B38M (Nanjing Legend Biotech /Janssen): Current Status of Development
Figure 15.17 Ciltacabtagene Autoleucel / LCAR-B38M (Nanjing Legend Biotech / Janssen) Sales Forecast, till 2030 (USD Million)
Figure 15.18 MB-CART19.1 (Miltenyi Biotec): Current Status of Development
Figure 15.19 MB-CART19.1 (Miltenyi Biotec) Sales Forecast, till 2030 (USD Million)
Figure 15.20 Descartes-11 (Cartesian Therapeutics): Current Status of Development
Figure 15.21 Descartes-11 (Cartesian Therapeutics) Sales Forecast, till 2030 (USD Million)
Figure 15.22 CD19 CAR-T (Sinobioway Cell Therapy): Current Status of Development
Figure 15.23 CD19 CAR-T (Sinobioway Cell Therapy) Sales Forecast, till 2030 (USD Million)
Figure 15.24 AUTO1 (Autolus): Current Status of Development
Figure 15.25 AUTO1 (Autolus) Sales Forecast, till 2030 (USD Million)
Figure 15.26 AUTO3 (Autolus): Current Status of Development
Figure 15.27 AUTO3 (Autolus) Sales Forecast, till 2030 (USD Million)
Figure 15.28 GPC3 CAR-T (Shanghai GeneChem): Current Status of Development
Figure 15.29 GPC3 CAR-T (Shanghai GeneChem) Sales Forecast, till 2030 (USD Million)
Figure 15.30 BCMA CAR-T (The Pregene (ShenZhen) Biotechnology): Current Status of Development
Figure 15.31 BCMA CAR-T (The Pregene (ShenZhen) Biotechnology) Sales Forecast, till 2030(USD Million)
Figure 15.32 CD19 CAR-T (The Pregene (ShenZhen) Biotechnology): Current Status ofDevelopment
Figure 15.33 CD19 CAR-T (The Pregene (ShenZhen) Biotechnology) Sales Forecast, till 2030 (USD Million)
Figure 15.34 CD19 CAR-T (Shanghai Bioray Laboratory): Current Status of Development
Figure 15.35 CD19 CAR-T (Shanghai Bioray Laboratory) Sales Forecast, till 2030 (USD Million)
Figure 15.36 Humanized CD19 CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology): Current Status of Development
Figure 15.37 Humanized CD19 CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology, Sales Forecast, till 2030 (USD Million)
Figure 15.38 PCAR-019 (PersonGen BioTherapeutics): Current Status of Development
Figure 15.39 PCAR-019 (PersonGen BioTherapeutics) Sales Forecast, till 2030 (USD Million)
Figure 15.40 TBI-1501 (Takara Bio): Current Status of Development
Figure 15.41 TBI-1501 (Takara Bio) Sales Forecast, till 2030 (USD Million)
Figure 15.42 IM19 CAR-T (Beijing Immunochina Medical Science & Technology): Current Status of Development
Figure 15.43 IM19 CAR-T (Beijing Immunochina Medical Science & Technology) Sales Forecast, till 2030 (USD Million)
Figure 15.44 CCT301 CAR-T (Shanghai Sinobioway Sunterra Biotech): Current Status of Development
Figure 15.45 CCT301 CAR-T (Shanghai Sinobioway Sunterra Biotech) Sales Forecast, till 2030 (USD Million)
Figure 15.46 BinD19 (Shenzhen BinDeBio): Current Status of Development
Figure 15.47 BinD19 (Shenzhen BinDeBio) Sales Forecast, till 2030 (USD Million)
Figure 15.48 CARCIK-CD19 (Formula Pharmaceuticals): Current Status of Development
Figure 15.49 CARCIK-CD19 (Formula Pharmaceuticals) Sales Forecast, till 2030 (USD Million)
Figure 15.50 EGFR CAR-T (The Beijing Pregene Science and Technology): Current Status of Development
Figure 15.51 EGFR CAR-T (The Beijing Pregene Science and Technology) Sales Forecast, till 2030 (USD Million)
Figure 15.52 Anti-MUC1 CAR-T Cell Therapy (Guangzhou Anjie Biomedical Technology): Current Status of Development
Figure 15.53 Anti-MUC1 CAR-T Cell Therapy (Guangzhou Anjie Biomedical Technology) Sales Forecast, till 2030 (USD Million)
Figure 15.54 PBCAR269A (Precision BioSciences and Servier): Current Status of Development
Figure 15.55 PBCAR269A (Precision BioSciences and Servier) Sales Forecast, till 2030 (USD Million)
Figure 15.56 CD123 CAR-T cells (Chongqing Precision Biotechnology): Current Status of Development
Figure 15.57 CD123 CAR-T cells (Chongqing Precision Biotechnology) Sales Forecast, till 2030 (USD Million)
Figure 15.58 BCMA CAR-T (Chongqing Precision Biotech): Current Status of Development
Figure 15.59 BCMA CAR-T (Chongqing Precision Biotech) Sales Forecast, till 2030 (USD Million)
Figure 15.60 P-BCMA-101 (Poseida Therapeutics / California Institute for RegenerativeMedicine): Current Status of Development
Figure 15.61 P-BCMA-101 (Poseida Therapeutics and California Institute for Regenerative Medicine) Sales Forecast, till 2030 (USD Million)
Figure 16.1 Channels Used for Promotional Campaigns
Figure 16.2 Promotional / Marketing Strategy: Product Website Analysis
Figure 16.3 Promotional / Marketing Strategy: Patient Support Services and Informative Downloads
Figure 16.4 Product Website Analysis: KYMRIAH®, Messages for Healthcare Professionals
Figure 16.5 Product Website Analysis: KYMRIAH®, Messages for Patients
Figure 16.6 Product Website Analysis: KYMRIAH®, Patient Support Program
Figure 16.7 KYMRIAH®, Presence in Conferences
Figure 16.8 Product Website Analysis: YESCARTA®, Messages for Healthcare Professionals
Figure 16.9 Product Website Analysis: YESCARTA®, Messages for Patients
Figure 16.10 Product Website Analysis: YESCARTA®, Kite Konnect
Figure 16.11 Product Website Analysis: YESCARTA®, Platform for Reporting Adverse Events  / Products Complaints and Requesting Medical Information
Figure 16.12 YESCARTA®, Presence in Conferences
Figure 18.1 Concluding Remarks: Overall Market Landscape
Figure 18.2 Concluding Remarks: Clinical Trial Analysis
Figure 18.3 Concluding Remarks: Partnerships & Collaborations and Funding and Investment Analysis
Figure 18.4 Concluding Remarks: Market Forecast

List Of Tables

Table 3.1 Types of Immunotherapies and Affiliated Mechanisms of Action
Table 3.2 FDA Approved Antibody based Cancer Therapeutics
Table 3.3 Key Characteristics of CAR-T Cells
Table 3.4 Comparison of First and Second-Generation CAR-Ts
Table 3.5 CD19 CAR-T Cells: Preclinical Results
Table 3.6 Other Targets under Clinical / Preclinical Studies for CAR-T Cell Therapies
Table 5.1 CAR-T Cell Therapies: Clinical Pipeline
Table 5.2 CAR-T Cell Therapies: Preclinical Pipeline
Table 6.1 CD19 CAR-T Cell Therapies: Competitive Landscape
Table 6.2 CD19 CAR-T Cell Therapies: Clinical Outcomes
Table 6.3 BCMA CAR-T Cell Therapies: Competitive Landscape
Table 6.4 BCMA CAR-T Cell Therapies: Clinical Outcomes
Table 6.5 Meso CAR-T Cell Therapies: Competitive Landscape
Table 6.6 Meso CAR-T Cell Therapies: Clinical Outcomes
Table 6.7 GD2 CAR-T Cell Therapies: Competitive Landscape
Table 6.8 GD2 CAR-T Cell Therapies: Clinical Outcomes
Table 6.9 CAR-T Cell Therapies: Principle Investigators
Table 6.10 CAR-T Therapies: Information on Constructs of Clinical Candidates
Table 7.1 CAR-T Cell Therapies: List of Clinical Trials
Table 7.2 Advanced Phase CAR-T Cell Therapies in China
Table 8.1 KYMRIAH®: Clinical Studies
Table 8.2 KYMRIAH®: Clinical Trial Endpoints (ALL)
Table 8.3 KYMRIAH®: Clinical Trial Endpoints (CLL / NHL / FL / MCL / CNSL)
Table 8.4 YESCARTA®: Clinical Studies
Table 8.5 YESCARTA®: Clinical Trial Endpoints
Table 8.6 TECARTUS® / Brexucabtagene Autoleucel: Clinical Studies
Table 8.7 TECARTUS® / Brexucabtagene Autoleucel: Clinical Trial Endpoints
Table 8.8 JCAR Series: Molecules in Clinical Phase of Development
Table 8.9 JCAR: CAR-T Design
Table 8.10 JCAR014: Clinical Studies
Table 8.11 JCAR017: Clinical Studies
Table 8.12 JCAR018: Clinical Studies
Table 8.13 JCAR020: Clinical Studies
Table 8.14 JCAR023: Clinical Studies
Table 8.15 JCAR024: Clinical Studies
Table 8.16 JCARH125: Clinical Studies
Table 8.17 JCAR Series: Clinical Trial Endpoints (Phase I/II / Phase II / Phase III)
Table 8.18 JCAR Series: Clinical Trial Endpoints (Phase I)
Table 8.19 JCAR: Dosage Regimen
Table 8.20 Idecabtagene Vicleucel / bb2121: Clinical Studies
Table 8.21 Idecabtagene Vicleucel / bb2121: Clinical Trial Endpoints
Table 8.22 Ciltacabtagene Autoleucel / LCAR-B38M / JUN-68284528: Clinical Studies
Table 8.23 Ciltacabtagene Autoleucel / LCAR-B38M / JUN-68284528: Clinical Trial Endpoints
Table 8.24 TBI-1501: Clinical Studies
Table 8.25 TBI-1501: Clinical Trial Endpoints
Table 8.26 TBI-1501: Dosage Regimen
Table 8.27 AUTO1: Clinical Studies
Table 8.28 AUTO3: Clinical Studies
Table 8.29 AUTO4: Clinical Studies
Table 8.30 Autolus’s Next Generation CAR-T Cell Therapies: Clinical Trial Endpoints
Table 8.31 Sinobioway Cell Therapy’s CD19 CAR-T Therapy: Clinical Studies
Table 8.32 Sinobioway Cell Therapy’s EPCAM CAR-T Therapy: Clinical Studies
Table 8.33 Sinobioway Cell Therapy’s Targeting CAR-T Cell Therapies: Clinical Trial Endpoints
Table 8.34 Phase I/II or Phase II CAR-T Cell Therapies from the Industry Players
Table 9.1 Comparison of Hodgkin’s and Non-Hodgkin’s Lymphoma
Table 9.2 Leukemia: List of Marketed Targeted Therapeutics
Table 9.3 Lymphoma: List of Marketed Targeted Therapeutics
Table 9.4 CAR-T Cell Therapies: Targets under Investigation for Leukemia
Table 9.5 CAR-T Cell Therapies: Targets under Investigation for Lymphoma
Table 9.6 Multiple Myeloma: List of Marketed Targeted Therapeutics
Table 9.7 CAR-T Cell Therapies: Targets under Investigation for Multiple Myeloma
Table 9.8 Melanoma: List of Marketed Targeted Therapeutics
Table 9.9 CAR-T Cell Therapies: Targets under Investigation for Melanoma
Table 9.10 Lung Cancer: List of Marketed Targeted Therapeutics
Table 9.11 CAR-T Cell Therapies: Targets under Investigation for Lung Cancer
Table 9.12 Pancreatic Cancer: List of Marketed Targeted Therapeutics
Table 9.13 CAR-T Cell Therapies: Targets under Investigation for Pancreatic Cancer
Table 9.14 Liver Cancer: List of Marketed Targeted Therapeutics
Table 9.15 CAR-T Cell Therapies: Targets under Investigation for Liver Cancer
Table 9.16 Breast Cancer: List of Marketed Targeted Therapeutics
Table 9.17 CAR-T Cell Therapies: Targets under Investigation for Breast Cancer
Table 9.18 Ovarian Cancer: List of Marketed Targeted Therapeutics
Table 9.19 CAR-T Cell Therapies: Targets under Investigation for Ovarian Cancer
Table 9.20 Bladder Cancer: List of Marketed Targeted Therapeutics
Table 9.21 Renal Cell Carcinoma: List of Marketed Targeted Therapeutics
Table 10.1 Editas Medicine: CRISPR / Cas9 Technology, Research Publications
Table 10.2 Editas Medicine: Funding Instances
Table 10.3 Editas Medicine: Partnerships & Collaborations
Table 10.4 Intellia Therapeutics: CRISPR / Cas9 Technology, Research Publications
Table 10.5 Intellia Therapeutics: Funding Instances
Table 10.6 Intellia Therapeutics: Collaborations
Table 10.7 CRISPR Therapeutics: CRISPR / Cas9 Technology, Research Publications
Table 10.8 CRISPR Therapeutics: Funding Instances
Table 10.9 CRISPR Therapeutics: Partnerships & Collaborations
Table 10.10 Beam Therapeutics: Funding Instances
Table 10.11 Beam Therapeutics: Collaborations
Table 10.12 Gracell Biotechnologies: Funding Instances
Table 10.13 Cellectis: Funding Instances
Table 10.14 Cellectis: Partnerships & Collaborations
Table 10.15 bluebird bio: megaTAL Technology, Research Publications
Table 10.16 bluebird bio: Funding Instances
Table 10.17 bluebird bio: Partnerships & Collaborations
Table 10.18 Sangamo Therapeutics: Funding Instances
Table 10.19 Sangamo Therapeutics: Partnerships & Collaborations
Table 10.20 Cogent Biosciences: Funding Instances
Table 10.21 Cogent Biosciences: Partnerships & Collaborations
Table 10.22 Celyad Oncology: Funding Instances
Table 10.23 Celyad Oncology: Partnerships & Collaborations
Table 10.24 Glycostem: Funding Instances
Table 10.25 Glycostem: Partnerships & Collaborations
Table 10.26 Intrexon: Funding Instances
Table 10.27 Intrexon: Collaborations
Table 10.28 Bellicum Pharmaceuticals: Key Switch Technologies
Table 10.29 Bellicum Pharmaceuticals: Switch Technologies, Research Publications
Table 10.30 Bellicum Pharmaceuticals: Funding Instances
Table 10.31 Bellicum Pharmaceuticals: Collaborations
Table 10.32 Theravectys: Funding Instances
Table 10.33 Technologies For CAR-T Safety Enhancement
Table 10.34 Formula Pharmaceuticals: Collaborations
Table 11.1 CAR-T Cell Therapy Market: List of Partnerships and Collaborations, 2005-2020 (till October)
Table 12.1 CAR-T Cell Therapies: Funding and Investments, 2000-2020 (till October)
Table 12.2 CAR-T Cell Therapies Summary of Investments
Table 13.1 Assessment Strategies for Different Manufacturing Processes
Table 13.2 Advantages and Disadvantages of Centralized and Decentralized Manufacturing Models
Table 13.3 Cell Therapy Manufacturing: Companies with In-house Capabilities
Table 13.4 Cell Therapy Manufacturing: Contract Manufacturers
Table 14.1 Price of Marketed Gene / Cell Therapies
Table 14.2 Price of Marketed Targeted Drugs
Table 14.3 CAR-T Cell Therapies: Expert Opinions on Pricing
Table 14.4 CAR-T Cell Therapies: Reimbursement Landscape
Table 15.1 CAR-T Cell Therapies: List of Forecasted Molecules
Table 15.2 KYMRIAH® (Novartis): Net Present Value (USD Million)
Table 15.3 KYMRIAH® (Novartis): Value Creation Analysis (USD Million)
Table 15.4 YESCARTA® (Gilead Sciences): Net Present Value (USD Million)
Table 15.5 YESCARTA® (Gilead Sciences): Value Creation Analysis (USD Million)
Table 15.6 TECARTUS®: (Gilead Sciences): Net Present Value (USD Million)
Table 15.7 TECARTUS®: (Gilead Sciences): Value Creation Analysis (USD Million)
Table 15.8 BREYANZI® / Lisocabtagene Maraleucel / JCAR017JCAR017 (Bristol Myers Squibb / Juno Therapeutics): Net Present Value (USD Million)
Table 15.9 BREYANZI® / Lisocabtagene Maraleucel / JCAR017JCAR017 (Bristol Myers Squibb / Juno Therapeutics): Value Creation Analysis (USD Million)
Table 15.10 Idecabtagene Vicleucel / bb2121 (bluebird bio / Bristol Myers Squibb): Net Present Value (USD Million)
Table 15.11 Idecabtagene Vicleucel / bb2121 (bluebird bio / Bristol Myers Squibb): Value Creation Analysis (USD Million)
Table 15.12 Ciltacabtagene Autoleucel / LCAR-B38M (Nanjing Legend Biotech / Janssen): Net Present Value (USD Million)
Table 15.13 Ciltacabtagene Autoleucel / LCAR-B38M (Nanjing Legend Biotech/ Janssen): Value Creation Analysis (USD Million)
Table 15.14 MB-CART19.1 (Miltenyi Biotec): Net Present Value (USD Million)
Table 15.15 MB-CART19.1 (Miltenyi Biotec): Value Creation Analysis (USD Million)
Table 15.16 Descartes-11 (Cartesian Therapeutics): Net Present Value (USD Million)
Table 15.17 Descartes-11 (Cartesian Therapeutics): Value Creation Analysis (USD Million)
Table 15.18 CD19 CAR-T (Sinobioway Cell Therapy): Net Present Value (USD Million)
Table 15.19 CD19 CAR-T (Sinobioway Cell Therapy): Value Creation Analysis (USD Million)
Table 15.20 AUTO1 (Autolus): Net Present Value (USD Million)
Table 15.21 AUTO1 (Autolus): Value Creation Analysis (USD Million)
Table 15.22 AUTO3 (Autolus): Net Present Value (USD Million)
Table 15.23 AUTO3 (Autolus): Value Creation Analysis (USD Million)
Table 15.24 GPC3 CAR-T (Shanghai Genechem): Net Present Value (USD Million)
Table 15.25 GPC3 CAR-T (Shanghai Genechem): Value Creation Analysis (USD Million)
Table 15.26 BCMA CAR-T (The Pregene (ShenZhen) Biotechnology): Net Present Value (USD Million)
Table 15.27 BCMA CAR-T (The Pregene (ShenZhen) Biotechnology): Value Creation Analysis (USD Million)
Table 15.28 CD19 CAR-T (The Pregene (ShenZhen) Biotechnology): Net Present Value (USD Million)
Table 15.29 CD19 CAR-T (The Pregene (ShenZhen) Biotechnology): Value Creation Analysis (USD Million)
Table 15.30 CD19 CAR-T (Shanghai Bioray Laboratory): Net Present Value (USD Million)
Table 15.31 CD19 CAR-T (Shanghai Bioray Laboratory): Value Creation Analysis (USD Million)
Table 15.32 Humanized CD19 CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology): Net Present Value (USD Million)
Table 15.33 Humanized CD19 CAR-T (Shanghai Unicar-Therapy Bio-medicineTechnology): Value Creation Analysis (USD Million)
Table 15.34 PCAR-019 (PersonGen BioTherapeutics): Net Present Value (USD Million)
Table 15.35 PCAR-019 (PersonGen BioTherapeutics): Value Creation Analysis (USDMillion)
Table 15.36 TBI-1501 (Takara Bio): Net Present Value (USD Million)
Table 15.37 TBI-1501 (Takara Bio): Value Creation Analysis (USD Million)
Table 15.38 IM19 CAR-T T (Beijing Immunochina Medical Science & Technology): Net Present Value (USD Million)
Table 15.39 IM19 CAR-T T (Beijing Immunochina Medical Science & Technology): Value Creation Analysis (USD Million)
Table 15.40 CCT301 CAR-T (Shanghai Sinobioway Sunterra Biotech): Net Present Value (USD
Table 15.41 CCT301 CAR-T (Shanghai Sinobioway Sunterra Biotech): Value Creation Analysis (USD Million)
Table 15.42 BinD19 (Shenzhen BinDeBio): Net Present Value (USD Million)
Table 15.43 BinD19 (Shenzhen BinDeBio): Value Creation Analysis (USD Million)
Table 15.44 CARCIK-CD19 (Formula Pharmaceuticals): Net Present Value (USD Million)
Table 15.45 CARCIK-CD19 (Formula Pharmaceuticals): Value Creation Analysis (USD Million)
Table 15.46 EGFR CAR-T (The Beijing Pregene Science and Technology): Net Present Value (USD Million)
Table 15.47 EGFR CAR-T (The Beijing Pregene Science and Technology): Value Creation Analysis (USD Million)
Table 15.48 ANTI-MUC1 CAR-T Cell Therapy (Guangzhou Anjie Biomedical Technology): Net Present Value (USD Million)
Table 15.49 ANTI-MUC1 CAR-T Cell Therapy (Guangzhou Anjie Biomedical Technology): Value Creation Analysis (USD Million)
Table 15.50 PBCAR269A (Precision BioSciences and Servier): Net Present Value (USD Million)
Table 15.51 PBCAR269A (Precision BioSciences and Servier): Value Creation Analysis (USD Million)
Table 15.52 CD123 CAR-T cells (Chongqing Precision Biotechnology): Net Present Value (USD Million)
Table 15.53 CD123 CAR-T cells (Chongqing Precision Biotechnology): Value Creation Analysis (USD Million)
Table 15.54 BCMA CAR-T (Chongqing Precision Biotech): Net Present Value (USD Million)
Table 15.55 BCMA CAR-T (Chongqing Precision Biotech): Value Creation Analysis (USD Million)
Table 15.56 P-BCMA-101 (Poseida Therapeutics / California Institute for RegenerativeMedicine): Net Present Value (USD Million)
Table 15.57 P-BCMA-101 (Poseida Therapeutics / California Institute for RegenerativeMedicine): Value Creation Analysis (USD Million)
Table 16.1 KYMRIAH®: Drug Overview
Table 16.2 YESCARTA®: Drug Overview
Table 17.1 Autolus: Company Profile
Table 17.2 bluebird bio: Company Profile
Table 17.3 CARsgen Therapeutics: Company Profile
Table 17.4 Celgene: Company Profile
Table 17.5 Cellectis: Company Profile
Table 17.6 Cellular Biomedicine Group: Company Profile
Table 17.7 Innovative Cellular Therapeutics: Company Profile
Table 17.8 Kite Pharma: Company Profile
Table 17.9 Kuur Therapeutics: Company Profile
Table 17.10 Noile-Immune Biotech: Company Profile
Table 17.11 Novartis: Company Profile
Table 17.12 Shanghai Genechem: Company Profile
Table 17.13 Sinobioway Cell Therapy: Company Profile
Table 17.14 Takara Bio: Company Profile
Table 17.15 Ziopharm Oncology: Company Profile
Table 20.1 CAR-T Cell Therapies: Distribution by Type of Developer
Table 20.2 CAR-T Cell Therapies: Distribution by Phase of Development
Table 20.3 CAR-T Cell Therapies: Distribution by Target Therapeutic Area
Table 20.4 CAR-T Cell Therapies: Distribution by Popular Target Indications
Table 20.5 CAR-T Cell Therapies: Distribution by Popular Target Antigen
Table 20.6 CAR-T Cell Therapies: Distribution by Source of T-Cells
Table 20.7 CAR-T Cell Therapies: Distribution by Route of Administration
Table 20.8 CAR-T Cell Therapies: Distribution by Dose Frequency
Table 20.9 CAR-T Cell Therapies: Distribution by Target Patient Segment
Table 20.10 CAR-T Cell Therapies: Distribution by Type of Therapy
Table 20.11 CAR-T Cell Therapies: Active Industry Players by Number of Therapies in Clinical Phase of Development
Table 20.12 CAR-T Cell Therapies: Active Industry Players by Number of Therapies in Preclinical Development
Table 20.13 CAR-T Cell Therapies: Active Non-Industry Players by Number of Therapies in Clinical Development
Table 20.14 CAR-T Cell Therapies: Active Non-Industry Players by Number of Therapies in Preclinical Development
Table 20.15 CAR-T Cell Therapies: Popular Targets in Hematological Cancer
Table 20.16 CAR-T Cell Therapies: Popular Targets in Solid Tumor
Table 20.17 CAR-Construction: Analysis by Generation of CAR-T Therapies
Table 20.18 CAR-Construction: Analysis by Type of scFv Antibody used in CAR-T Therapies
Table 20.19 CAR-Construction: Analysis by Type of Vector
Table 20.20 CAR-Construction: Analysis by Type of Co-Stimulatory Domain(s)
Table 20.21 CAR-T Cell Therapy Clinical Trials: Distribution by Trial Registration Year
Table 20.22 CAR-T Cell Therapy Clinical Trials: Distribution by Number of Clinical Trials and Geography (Pre-2016 and 2019)
Table 20.23 Partnerships and Collaborations: Cumulative Year-Wise Trend, 2005-2020
Table 20.24 Partnerships and Collaborations: Distribution by Type of Partnership
Table 20.25 Partnerships and Collaborations: Distribution by Type of Partnership, Pre-2015 and 2015-2020
Table 20.26 Partnerships and Collaborations: Distribution by Type of Partner
Table 20.27 Partnerships and Collaborations: Distribution by Individual Products
Table 20.28 Partnerships and Collaborations: Most Active Industry Players
Table 20.29 Partnerships and Collaborations: Most Active Non-Industry Players
Table 20.30 Partnerships and Collaborations: Most Active Contract Manufacturers
Table 20.31 Partnerships and Collaborations: Intercontinental and Intracontinental Manufacturing Agreements
Table 20.32 Partnerships and Collaborations: Regional Distribution
Table 20.33 Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
Table 20.34 Funding and Investment Analysis: Cumulative Year-wise Trend of Funding Instances, Pre 2013-2020 (till October)
Table 20.35 Funding and Investment Analysis: Distribution by Cumulative Amount Invested, Pre 2013-2020 (USD Million)
Table 20.36 Funding and Investment Analysis: Distribution of Instances by Type of Funding
Table 20.37 Funding and Investment Analysis: Distribution of Total Amount Invested by Type of Funding (USD Million)
Table 20.38 Most Active Players: Distribution by Number of Instances
Table 20.39 Funding and Investments: Distribution by Types of Investor
Table 20.40 Most Active Players: Distribution by Number of Instances
Table 20.41 Funding and Investment Analysis: Distribution by Geography
Table 20.42 Funding and Investment Analysis: Distribution of Amount Invested across Different Countries (USD Million)
Table 20.43 Overall CAR-T Cell Therapies Market, 2021-2030, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 20.44 CAR-T Cell Therapies Market: Distribution by Target Indication(s), 2025 and 2030 (USD Billion)
Table 20.45 CAR-T Cell Therapies Market: Distribution by Target Antigen(s), 2025 and 2030 (USD Billion)
Table 20.46 CAR-T Cell Therapies Market: Key Players, 2025 and 2030 (USD Billion)
Table 20.47 CAR-T Cell Therapies Market: Distribution by Geography, 2025 and 2030 (USD Billion)
Table 20.48 KYMRIAH® (Novartis) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 20.49 YESCARTA® (Gilead Sciences) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 20.50 TECARTUS® (Gilead Sciences) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 20.51 Idecabtagene Vicleucel / bb2121 (bluebird bio / Bristol Myers Squibb) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 20.52 Ciltacabtagene Autoleucel / LCAR-B38M CAR-T (Nanjing Legend Biotech / Janssen) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 20.53 JCAR017 (Juno Therapeutics / Celgene / WuXi AppTec) Sales Forecast, Conservative, 
Table 20.54 MB-CART19.1 (Miltenyi Biotec) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 20.55 Descartes-11 (Cartesian Therapeutics) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 20.56 CD19 CAR-T (Sinobioway Cell Therapy) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 20.57 AUTO1 (Autolus) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 20.58 AUTO3 (Autolus) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 20.59 GPC3 CAR-T (Shanghai GeneChem) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 20.60 BCMA CAR-T (The Pregene (ShenZhen) Biotechnology) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 20.61 CD19 CAR-T (The Pregene (ShenZhen) Biotechnology) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 20.62 CD19 CAR-T (Shanghai Bioray Laboratory) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 20.63 Humanized CD19 CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 20.64 PCAR-019 (PersonGen BioTherapeutics) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 20.65 TBI-1501 (Takara Bio) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 20.66 IM19 CAR-T (Beijing Immunochina Medical Science & Technology) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 20.67 CCT301 CAR-T (Shanghai Sinobioway Sunterra Biotech) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 20.68 BinD19 (Shenzhen BinDeBio) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 20.69 CARCIK-CD19 (Formula Pharmaceuticals) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 20.70 EGFR CAR-T (The Beijing Pregene Science and Technology) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 20.71 Anti-MUC1 CAR-T (Guangzhou Anjie Biomedical Technology) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 20.72 PBCAR269A (Precision BioSciences) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 20.73 CD123 CAR-T Cells (Chongqing Precision Biotechnology) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 20.74 BCMA CAR-T (Chongqing Precision Biotech) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 20.75 P-BCMA-101 (Poseida Therapeutics) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)

List Of Companies

The following companies / institutes / government bodies and organizations have been mentioned in this report.

1. 3P Biopharmaceuticals
2. AbbVie
3. AbCellera 
4. AbCheck
5. AbClon
6. Abeona Therapeutics
7. Abzena
8. Academy of Military Medical Sciences (AMMS)
9. Acıbadem Altunizade Hospital
10. Acibadem University
11. ACROBiosystems
12. Adaptimmune
13. Adicet Bio
14. Adimab
15. Advanced Cell Therapy Laboratory (ACTL)
16. Advent Bioservices
17. Aeon Biotherapeutics
18. Affiliated Hospital of Jiangnan University
19. Affiliated Hospital to Academy of Military Medical Sciences
20. AffyImmune Therapeutics
21. AgenTus Therapeutics
22. Agilent Technologies
23. Agreen Biotech 
24. Alberta Cell Therapy Manufacturing (ACTM)
25. Alexandria Real Estate Equities
26. Allele Biotechnology and Pharmaceuticals
27. Allife Medicine 
28. Allogene Therapeutics
29. Altor Bioscience
30. Amgen
31. Angel Biotechnology
32. Anhui Anke Biotechnology 
33. Anhui Provincial Hospital
34. ANTAGENE
35. Anterogen
36. Arbele
37. Argos Therapeutics
38. Artiva Biotherapeutics 
39. Aspire Health Science
40. Astellas Pharma
41. Astero Bio
42. Atara Biotherapeutics
43. Atossa Therapeutics
44. Aurora Biopharma
45. Autolus
46. Avacta
47. Avalon GloboCare
48. Bambino Gesù Hospital and Research Institute
49. Baxalta
50. Baylor College of Medicine
51. Be The Match BioTherapies
52. Beam Therapeutics
53. Beijing 302 Hospital
54. Beijing Biohealthcare Biotechnology
55. Beijing Boren Hospital
56. Beijing Cancer Hospital
57. Beijing Children's Hospital
58. Beijing Doing Biomedical Technology
59. Beijing HuiNengAn Biotech
60. Beijing Immunochina Medical Science & Technology
61. Beijing Lu Daopei Hospital
62. Beijing Mario Biotech
63. Beijing Sanbo Brain Hospital
64. Beijing Sanwater Biological Technology
65. Beijing Tsinghua Chang Gung Hospital
66. Beijing Yimiao Shenzhou Pharmaceutical
67. Bellicum Pharmaceuticals
68. Beth Israel Deaconess Medical Center (BIDMC)
69. Bio Elpida
70. BioAtla
71. BioCardia
72. Bioceltech Therapeutics
73. Bio-Gene Technology
74. Bioinova
75. BioLife Solutions
76. Biological & Cellular GMP Manufacturing Facility
77. BioNTech
78. BioRestorative Therapies
79. Biosceptre International
80. BioTherapeutics Unit (BTU)
81. bluebird bio
82. Bone Therapeutics
83. Boya Jiyin
84. BoYuan RunSheng Pharma (Hangzhou)
85. Bristol Myers Squibb
86. Cabaret Biotech
87. Calibr
88. California Institute for Regenerative Medicine
89. Cancer Research UK
90. Cancer Prevention Research Institute of Texas
91. Capricor Therapeutics
92. Carina Biotech
93. Carlos III Health Institute (Instituto de Salud Carlos III)
94. CARsgen Therapeutics
95. Cartesian Therapeutics
96. Cartherics
97. Case Comprehensive Cancer Center
98. Case Western Reserve University
99. Casebia Therapeutics
100. Celdara Medical
101. Celgene
102. Cell and Gene Therapy Catapult
103. Cell Design Labs
104. Cell Manufacturing Technologies (CMaT)
105. Cell Therapies Core
106. Cell Therapy and Regenerative Medicine
107. Cell Therapy Manufacturing Cooperative Research Centre (CTM CRC)
108. Cell Therapy Suite
109. Cellectis
110. CELLforCURE
111. Cellin Technologies
112. Cells for Sight Stem Cell Therapy Research Unit
113. Cellular Biomedicine Group (CBMG)
114. Cellular Therapy Core (CTC)
115. Cellular Therapy Integrated Services (CTIS)
116. Celyad Oncology
117. Center for Cell and Gene Therapy
118. Center for Gene and Cell Processing (CGCP)
119. Center for International Blood and Marrow Transplant Research
120. Center of Excellence for Cellular Therapy (C3i)
121. Central South University
122. Centre for Biological Engineering
123. Centre for Cell and Vector Production (CCVP)
124. Centre for Cell Manufacturing Ireland (CCMI)
125. Centre for Stem Cell Research (CSCR)
126. Changhai Hospital
127. Changshu Frist People's Hospital
128. Changzheng Hospital
129. Children’s Hospital of Philadelphia
130. Children's GMP / GMP facility St. Jude Children's Research Hospital
131. Children's Hospital and Health System Foundation
132. Children's Hospital of Fudan University
133. Children's Hospital of Philadelphia
134. Children's Mercy Hospital Kansas City
135. China (Nanjing) Cell Valley (CNCV)
136. China Immunotech (Beijing) Biotechnology
137. China Meitan General Hospital
138. China Regenerative Medicine International (CRMI)
139. Chinese Academy of Sciences
140. Chinese PLA General Hospital
141. Chongqing Precision Biotech
142. City of Hope Medical Center
143. City of Hope National Medical Center
144. Cleans Cells
145. Clinical Cell and Vaccine Production Facility (CVPF)
146. Clinical Research Facility
147. Cognate BioServices
148. Columbia University
149. Connell and O'Reilly Families Cell Manipulation Core Facility (CMCF)
150. Cook Myosite
151. Corondo Biosciences
152. Creative Biolabs
153. CRISPR Therapeutics
154. Cryoport
155. CSIRO
156. CTI Clinical Trial and Consulting Services
157. CureSearch for Children's Cancer
158. CytoLumina Technologies
159. CytoMed Therapeutics
160. Cytopeutics
161. Dana-Farber / Harvard Cancer Center
162. Dana-Farber Cancer Institute
163. Dartmouth College
164. Delenex Therapeutics
165. Dendreon
166. DLR German Aerospace Center
167. Dongguan People's Hospital
168. Duke University
169. Editas Medicine
170. Eli Lilly
171. Emory Personalized Immunotherapy Core
172. Endocyte
173. Eureka Therapeutics
174. Eutilex
175. EXUMA Biotechnology
176. Fate Therapeutics
177. Federal Research Institute of Pediatric Hematology
178. FetoLumina Technologies
179. First Affiliated Hospital of Chengdu Medical College
180. First Affiliated Hospital of Chongqing Medical University
181. First Affiliated Hospital of Harbin Medical University
182. First Affiliated Hospital of Wenzhou Medical University
183. First Affiliated Hospital of Zhejiang University
184. First Hospital of Jilin University
185. First People's Hospital of Foshan
186. Five Prime Therapeutics
187. Fondazione Matilde Tettamanti Menotti De Marchi Onlus
188. Fondo Social La Caixa
189. Fondos ARI (Assistencia Recerca Intensiva)
190. Forevertek Biotechnology
191. Formula Pharmaceuticals
192. Fosun Kite Biotechnology
193. Fosun Pharma
194. Foundation for Biomedical Research and Innovation at Kobe
195. Fraunhofer Institute for Cell Therapy and Immunology
196. Fred Hutchinson Cancer Research Center
197. Froceth
198. Fujian Medical University
199. Fujifilm
200. Fundamenta Therapeutics
201. Gamida Cell
202. Gates Biomanufacturing Facility
203. GC Pharma
204. GE Research
205. GE Healthcare Life Sciences
206. GenCure
207. Gene and Cell Therapy Lab
208. Genentech
209. General Hospital of People’s Liberation Army (PLAGH)
210. GenIbet Biopharmaceuticals
211. Genus Oncology
212. Gilead Sciences
213. GlaxoSmithKline
214. Glycostem Therapeutics
215. GlyTherix
216. Gracell Biotechnologies
217. Great Ormond Street Hospital for Children (GOSH)
218. Guangdong General Hospital
219. Guangdong Zhaotai InVivo Biomedicine
220. Guangzhou Eighth People’s Hospital
221. Guangzhou Anjie Biomedical Technology
222. Guangzhou First People's Hospital
223. Guy's and St Thomas' Facility
224. H. Lee Moffitt Cancer Center and Research Institute
225. Harvard University
226. Hebei Senlang Biotechnology
227. Hebei Yanda Lu Daopei Hospital
228. Hefei Binhu Hospital
229. Hefei First People’s Hospital
230. Helix BioPharma
231. Henan Cancer Hospital
232. Henan Hualong Biotech
233. Henan Provincial People's Hospital
234. Histocell
235. Hitachi Chemical Advanced Therapeutics Solutions
236. Holostem Terapie Avanzate
237. Horizon Discovery
238. Hrain Biotechnology
239. HuaDao (Shanghai) Biomedical
240. Huaian First People's Hospital
241. Huazhong University of Science and Technology
242. Hunan Provincial People's Hospital
243. Hunan Yongren Medical Innovation
244. Hunan Zhaotai Yongren Biotech
245. iCAR Bio Therapeutics
246. iCarTAB BioMed
247. iCell Gene Therapeutics
248. Icell Kealex Therapeutics
249. ICON
250. Immetacyte
251. Immune Therapeutics
252. Immunovative Therapies
253. Imperial College London
254. Inhibrx
255. Innovative Cellular Therapeutics
256. Institut Curie
257. Institute of Cancer Research
258. Institute of Hematology & Blood Diseases Hospital
259. Institute of Translational Health Sciences
260. Intellia Therapeutics
261. Interdisciplinary Stem Cell Institute
262. International Stem Cell
263. Intrexon
264. Invectys
265. Janssen
266. Japanese Society for Regenerative Medicine
267. Jiangsu Province Hospital of Traditional Chinese Medicine
268. Jiangyin People's Hospital
269. Jichi Medical University
270. Jingjiang People's Hospital
271. Jingzhou Central Hospital
272. Jiujiang University Affiliated Hospital
273. John Goldman Centre for Cellular Therapy
274. Jonsson Comprehensive Cancer Center
275. Juno Therapeutics
276. Juventas Cell Therapy
277. JW Therapeutics
278. Kadimastem
279. KAEDI
280. Karolinska institute
281. KBI Biopharma
282. Kecellitics Biotech
283. Kiadis Pharma
284. King's College London
285. Kite Pharma
286. Kurr Therapeutics
287. Laboratory for Cell and Gene Medicine
288. Legend Biotech
289. Leucid Bio
290. Leukemia & Lymphoma Society
291. Leukemia Research Foundation
292. Lianyungang Hospital Affiliated Bengbu Medical College
293. Life Technologies
294. Liminatus Pharma
295. Lineage Cell Therapeutics
296. Lion TCR
297. Living Pharma
298. Longeveron
299. Lonza
300. Loughborough University
301. Loyola University Medical Center
302. LUMICKS
303. MabQuest
304. MabVax Therapeutics Holdings
305. Malaghan Institute of Medical Research
306. Marino Biotechnology
307. Marker Therapeutics
308. Massachusetts General Hospital
309. MaSTherCell
310. Max Delbrück Center for Molecular Medicine
311. MaxCyte
312. McMaster University
313. McMaster University- Biomedical Engineering and Advanced Manufacturing (BEAM)
314. MD Anderson Cancer Center
315. Medical College of Wisconsin
316. MedImmune
317. MEDINET
318. Medipost
319. Medisix Therapeutics
320. MedStar Georgetown University Hospital
321. Memorial Sloan Kettering Cancer Center
322. Merck
323. Mesoblast
324. Mie University
325. Miller School of Medicine
326. Miltenyi Biomedicine
327. Minerva Biotechnologies
328. MingJu Therapeutics
329. Minovia Therapeutics
330. Moffitt Cancer Center
331. Molecular and Cellular Therapeutics
332. MolMed
333. Mustang Bio
334. Nanfang Hospital of Southern Medical
335. Nanjing Bioheng Biotech
336. Nanjing Children's Hospital
337. Nanjing KAEDI Biotech
338. NantKwest
339. National Cancer Center Japan
340. National Cancer Institute
341. National Heart, Lung, and Blood Institute
342. National Institutes of Health
343. National Marrow Donor Program
344. National University of Ireland Galway
345. NeoSTEM
346. Netherlands Cancer Institute
347. Neuralstem
348. Newcastle Advanced Therapies
349. New Jersey Innovation Institute (NJII)
350. NHS Blood and Transplant
351. Nikon CeLL innovation
352. Ningbo Cancer Hospital
353. NIPRO
354. Nkarta
355. Nohla Therapeutics
356. Noile-Immune Biotech
357. Notch Therapeutics
358. Novadip
359. Novartis
360. Obsidian Therapeutics
361. Oncodesign Biotechnology
362. Oncora Medical
363. ONCOTracker
364. OnCyte
365. oNKo-innate
366. ONO Pharmaceutical
367. Opus Bio
368. Orgenesis
369. Ospedale Pediatrico Bambino Gesù (OPBG)
370. Otsuka Pharmaceutical
371. Ottawa Hospital Research Institute
372. Oxford BioMedica
373. Oxford MEStar and AK (Suzhou) Biomedical
374. panCELLa
375. Parker Institute for Cancer Immunotherapy
376. Peking Union Medical College Hospital
377. Peking University
378. Peking University People's Hospital
379. PeproMene Bio
380. PersonGen BioTherapeutics
381. Peter MacCallum Cancer Centre
382. Pfenex
383. PharmaBio
384. Pharmicell
385. Phio Pharmaceuticals
386. Pinze Lifetechnology
387. Pluristem Therapeutics
388. Poseida Therapeutics
389. Praxis Pharmaceutical
390. Precision Biosciences
391. Pregenen
392. Princess Margaret Hospital
393. ProMab Biotechnologies
394. Promethera Biosciences
395. Protheragen
396. Provia Laboratories
397. Purdue University
398. PureTech Health
399. Q-Gen Cell Therapeutics
400. QIMR Berghofer Medical Research Institute
401. Rayne Cell Therapy Suite (King's College London)
402. Regeneron Pharmaceuticals
403. ReNeuron
404. RenJi Hospital
405. Research and Development Center for Cell Therapy (RDC)
406. resTORbio
407. Rexgenero
408. Riyadh Pharmaceutical
409. Rockland Immunochemicals
410. Roger Williams Medical Center
411. Roslin Cells
412. Roswell Park Cancer Institute
413. Royal Adelaide Hospital Cancer Centre
414. Rubius Therapeutics
415. Ruijin Hospital
416. Russian Direct Investment Fund
417. S.Biomedics
418. Samsung BioLogics
419. San Diego Regenerative Medicine Institute
420. Sangamo Therapeutics
421. Scientific and Technological Research Council of Turkey
422. SCM Lifescience
423. Scotia Biologics
424. Scottish National Blood Transfusion Service (SNBTS)
425. Scripps Research
426. Seattle Cancer Care Alliance
427. Seattle Children's Hospital
428. Seattle Children's Research Institute
429. Second Affiliated Hospital of Guangzhou Medical University
430. Second Affiliated Hospital of Nanchang University
431. Second Affiliated Hospital of Xi'an Jiaotong University
432. Second Military Medical University
433. Second Xiangya Hospital of Central South University
434. Sensei Biotherapeutics
435. Servier
436. Shangai Cancer Institute (SCI)
437. Shanghai Tenth People’s Hospital
438. Shanghai Sixth People's Hospital
439. Shanghai Biomed-union Biotechnology
440. Shanghai Bioray Laboratory
441. Shanghai Cell Therapy Group
442. Shanghai Cell Therapy Research Institute
443. Shanghai Changzheng Hospital
444. Shanghai Chest Hospital
445. Shanghai Children's Medical Center
446. Shanghai East Hospital
447. Shanghai GeneChem
448. Shanghai International Medical Center
449. Shanghai Jiao Tong University School of Medicine
450. Shanghai Longyao Biotechnology
451. Shanghai PerHum Therapeutics
452. Shanghai Public Health Clinical Center (SPHCC)
453. Shanghai Tongren Hospital
454. Shanghai Tongji Hospital
455. Shanghai UniCAR-Therapy Bio-Medicine Technology
456. Shanghai Zhongshan Hospital
457. Sheba Medical Center
458. Shenzhen Binder Biotechnology
459. Shenzhen Children's Hospital
460. Shenzhen Geno-immune Medical Institute
461. Shenzhen Hospital of Southern Medical University
462. Shenzhen Institute for Innovation and Translational Medicine
463. Shenzhen Second People's Hospital
464. Shenzhen University (SZU)
465. ShiJiaZhuang Zhongxi Children Hospital
466. Sichuan University
467. Sidney Kimmel Cancer Center
468. Simcere Pharmaceutical
469. Sinobioway Cell Therapy
470. Sorrento Therapeutics
471. SOTIO
472. South London and Maudsley NHS Foundation Trust
473. Southern Medical University
474. SpringWorks Therapeutics
475. St. Baldrick's Foundation
476. St. Jude Children's Research Hospital
477. St. Michael’s Hospital
478. Stage Cell Therapeutics
479. Stanford University
480. Stem Cell Institute
481. Stemedica Cell Technologies
482. Stemmatters
483. Stempeutics Research
484. Stony Brook University
485. Stratophase
486. Sumitomo Dainippon Pharma
487. Sun Yat-Sen University
488. Suzhou Municipal Hospital
489. Sydney Cell and Gene Therapy
490. Synthace
491. SZU General Hospital
492. Takara Bio
493. Takeda Pharmaceutical
494. Tang Du Hospital
495. Targazyme
496. TC BioPharm
497. Tel Aviv Sourasky Medical Centre (Ichilov)
498. TeneoBio
499. Terumo BCT
500. Tessa Therapeutics
501. Texas Children's Hospital
502. The Affiliated Hospital of Guizhou Medical University
503. The Affiliated Drum Tower Hospital of Nanjing University Medical School
504. The Beijing Pregene Science and Technology
505. The First Affiliated Hospital of Anhui Medical University
506. The First Affiliated Hospital of Guangdong Pharmaceutical University
507. The First Affiliated Hospital of Kunming Medical University
508. The First Affiliated Hospital of Nanchang University
509. The First Affiliated Hospital of Soochow University
510. The First Affiliated Hospital of Zhengzhou University
511. The First Affiliated Hospital with Nanjing Medical University
512. The First People's Hospital of Yuhang District
513. The First People's Hospital of Yunnan
514. The Health Sciences Authority
515. The Islet and Cellular Transplant Facility
516. The Krembil Good Manufacturing Practice Cell Facility
517. The Ohio State University
518. The Philip S. Orsino Cell Therapy Facility
519. The Pregene ShenZhen Biotechnology
520. The Second Affiliated Hospital of Chongqing Medical University
521. The Second Affiliated Hospital of Hainan Medical University
522. The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine
523. The Second Hospital of Anhui Medical University
524. The Second Hospital of Hebei Medical University
525. The Second Hospital of Nanjing Medical University
526. The Second Military Medical University (SMMU)
527. The Second People's Hospital of Huai'an
528. The Seventh Affilliated Hospital
529. The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
530. The Sixth Affiliated Hospital of Wenzhou Medical University
531. The Third Affiliated Hospital of Southern Medical University
532. The Wistar Institute
533. Therapeutic Cell Production Core (TCPC)
534. ThermoFisher
535. Third Military Medical University
536. Tianjin Medical University Cancer Institute and Hospital
537. Tianjin Pharmacn Medical Technology
538. Tianjin People's Hospital
539. TILT Biotherapeutics
540. Timmune Biotech
541. Tmunity Therapeutics
542. Tongji University
543. Toni Stephenson Lymphoma Center
544. ToolGen
545. Torque Pharmaceuticals
546. TrakCel
547. Transgene
548. Transposagen Biopharmaceuticals
549. TreeFrog Therapeutics
550. TriArm Therapeutics
551. Trinity College
552. Tri-Service General Hospital
553. TVAX Biomedical
554. UC Davis Good Manufacturing Practice Laboratory
555. UCLA Human Gene and Cell Therapy Facility (HGCTF)
556. UNC Lineberger Comprehensive Cancer Center
557. Union Stem Cell & Gene Engineering
558. United States Department of Defense
559. University College London
560. University Health Network (UHN)
561. University Hospital Basel
562. University Hospital Heidelberg
563. University Hospital Würzburg
564. University of Birmingham
565. University of California
566. University of Cologne
567. University of Colorado
568. University of Florida
569. University of Manchester
570. University of Miami
571. University of Milano-Bicocca
572. University of Minnesota
573. University of North Carolina Lineberger Comprehensive Cancer Center
574. University of Oxford
575. University of Pennsylvania
576. University of Rochester
577. University of Technology Sydney
578. University of Texas
579. University of Toronto
580. University of Utah
581. University of Washington
582. University of Zurich
583. Uppsala University
584. Upstate Stem Cell cGMP Facility
585. UWELL Biopharma
586. V Foundation
587. Vaccinogen
588. Vecura (Karolinska University Hospital)
589. Vericel
590. VetStem Biopharma
591. ViroMed Laboratories
592. Vitruvian Networks
593. Waisman Biomanufacturing
594. Washington University
595. Weill Cornell Medical College of Cornell University
596. Wellington Zhaotai Therapies
597. West China Hospital
598. WindMIL Therapeutics
599. Wuhan Bio-Raid Biotechnology
600. Wuhan Sian Medical Technology
601. Wuhan Union Hospital
602. WuXi AppTec
603. Xiangyang Central Hospital
604. Xijing Hospital
605. Xinqiao Hospital
606. Xuanwu Hospital of Capital Medical University
607. Xuzhou Medical University
608. Yake Biotechnology
609. Yale School of Medicine
610. Yamaguchi University
611. Yan'an Affiliated Hospital of Kunming Medical University
612. Yuan Yi Biotechnology
613. Yunnan Cancer Hospital
614. Zelluna Immunotherapy
615. Zhangjiagang First People's Hospital
616. Zhejiang University (ZJU)
617. Zhujiang Hospital
618. Ziopharm Oncology